文献速递真实世界研究与卫生经济流行病学与生物统计

评估EMA政策0070与加拿大卫生部法规下匿名化临床研究报告的重识别风险

Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations.
PubMed 文献 · Trials · 2020-02-18

该研究实证检验按EMA与加拿大卫生部指南匿名化的临床研究报告能否充分保护患者隐私。以美国500名患者为目标对一份非甾体抗炎药滴眼液试验的匿名报告进行重识别,仅发现6例低置信度疑似匹配,每例耗时24.2小时,提示匿名化指南可提供充分隐私保护。

要点

  • 按EMA与加拿大卫生部指南匿名化的临床研究报告重识别风险低。
  • 仅发现6例低置信度疑似匹配,未确认真实身份。
  • 社交媒体与死亡记录是获取疑似匹配最有用的信息来源。

核心结论

  • EMA与加拿大卫生部的匿名化指南可为患者提供充分的隐私保护。
  • 攻击模式可为完善指南推荐的方法学提供参考。

研究设计与样本

  • 实证研究,对一份非甾体抗炎药处方滴眼液试验的匿名化临床研究报告进行重识别测试。
  • 目标为美国500名患者,仅报告与真实身份的疑似匹配。

主要发现

  • 共识别出6例低置信度评分的疑似匹配。
  • 每例疑似匹配耗时24.2小时。
  • 社交媒体和死亡记录为获取疑似匹配提供了最有用的信息。

临床怎么用

  • 药企按EMA政策0070与加拿大卫生部法规匿名化临床研究报告时,可参考该结果评估隐私保护充分性。
  • 可关注社交媒体与死亡记录等攻击途径,以进一步优化匿名化方法。

局限性

  • 仅针对一份非甾体抗炎药滴眼液试验的匿名化报告进行测试。
  • 目标仅为美国500名患者,结果外推需谨慎。
  • 仅报告疑似匹配,未确认真实身份。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regulatory agencies, such as the European Medicines Agency and Health Canada, are requiring the public sharing of clinical trial reports that are used to make drug approval decisions. Both agencies have provided guidance for the quantitative anonymization of these clinical reports before they are shared. There is limited empirical information on the effectiveness of this approach in protecting patient privacy for clinical trial data. METHODS: In this paper we empirically test the hypothesis that when these guidelines are implemented in practice, they provide adequate privacy protection to patients. An anonymized clinical study report for a trial on a non-steroidal anti-inflammatory drug that is sold as a prescription eye drop was subjected to re-identification. The target was 500 patients in the USA. Only suspected matches to real identities were reported. RESULTS: Six suspected matches with low confidence scores were identified. Each suspected match took 24.2 h of effort. Social media and death records provided the most useful information for getting the suspected matches. CONCLUSIONS: These results suggest that the anonymization guidance from these agencies can provide adequate privacy protection for patients, and the modes of attack can inform further refinements of the methodologies they recommend in their guidance for manufacturers.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Branson J, Good N, Chen JW, et al. Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations. Trials. 2020. PMID: 32070405. doi:10.1186/s13063-020-4120-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。